Navigation Links
NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Date:3/4/2009

Product Candidate NVC-422 Demonstrates Ability to Treat Subcutaneous Infections

EMERYVILLE, Calif., March 4 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a clinical stage biopharmaceutical company, today announced that new preclinical data related to NVC-422, the lead molecule in NovaBay's, proprietary Aganocide(R) class of compounds, will be presented at the American Academy of Dermatology (AAD) 67th Annual Meeting in San Francisco during March 6-10, 2009. NovaBay is focused on developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells for the treatment and prevention of bacterial, fungal, and viral infections without developing resistance.

"We have new data at the upcoming AAD annual meeting that further demonstrate the potential of NVC-422 and our Aganocide class of compounds to effectively treat chronic and common fungal skin infections," said Dr. Ron Najafi, chairman and chief executive officer. "Data from the Center for Medical Mycology at Case Western Reserve University Hospitals confirm how our novel, anti-infective agent in an animal model is highly effective not only on the skin surface, but also showed potent ability to kill subcutaneous organisms by route of the hair follicles."

Following are the details on the poster presentation.

    Saturday, March 7
    Poster Title: "Efficacy of NVC 422 in the Topical Treatment of
    Dermatophytosis in a Guinea Pig Model"
    Professor Mahmoud Ghannoum et al
    Time: 9:20 a.m. Pacific Time
    Moscone Center North, Hall E, Abstract #2405

About NVC-422

NVC-422 is the lead molecule in NovaBay's Aganocide class of compounds. NVC-422 is a non-antibiotic, stable analog of an anti-infective molecule produced by white blood cells. NovaBay b
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. NovaBay announces third quarter 2007 financial results
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Chicago, IL (PRWEB) , ... July 07, 2015 ... ... organized the only industry group whose board is limited to permit holders. The ... vision on how to move the industry forward and are committed to making ...
(Date:7/7/2015)... ... ... the end of June Pacific Prime Renewals team in Hong Kong announced that they ... Renewals Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the use of ... send anything between 300 and 600 pieces of paper per month. Not to mention A4 ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency ... its patient community using its IDF ePHR, an electronic personal health record powered ... (PI) to easily track their health information, including symptoms, diagnoses, medications, infusions and ...
(Date:7/7/2015)... ... ... Parents and guardians of teenagers or young adults will be interested in ... for drug and alcohol abuse located in Southwest Michigan. A recently released study by ... increase in the “club drug” use among high school seniors. The blog post offers ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... of telemedicine programs in communities throughout Georgia, announces the launch of the first ... rural communities of Hancock County, GA. The new program will not only provide ...
Breaking Medicine News(10 mins):Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2
... causing inflammation of the arteries. There is mounting evidence that gum ... uncovers a link between the mouth and the heart - C ... that people with gum disease have higher than normal CRP levels. ... circulation via the gums, and then trigger the liver to make ...
... guidelines issued recently could mean that as many as one ... of a class of prescription drugs called statins. The recommendations ... number of Americans taking statins. The panel hopes that expanded ... exercise -- will help reduce the close to 1.1 million ...
... of hepatitis virus not believed to cause illness may improve ... AIDS. In two new studies, HIV-positive people who were also ... than other people infected with HIV. Researchers suspect that hepatitis ... survival by keeping HIV from replicating as often. // ...
... suggests that those who eat the healthiest diets also eat ... The Healthy Eating Index (HEI) is a measure that US ... This emphasises your eating pattern rather than intake of specific ... grains, vegetables, fruit, milk or meat, ten more possible points ...
... bonds in the body's blood vessels significantly decreases the ... study conducted by National Institute on Aging (NIA) scientists ... a new treatment for high blood pressure, heart failure, ... bonds or crosslinks created in the arteries and other ...
... hampered by high rates of relapse, even after prolonged drug ... VU Medical Center in the Netherlands and the intramural laboratories ... a process in the brain that may lead to a ... // , In studies using rats, ...
Cached Medicine News:
(Date:7/7/2015)... , July 7, 2015 Hill-Rom,s recent ... $2 billion in cash and stock means the ... market, according to Kalorama Information. The healthcare market ... the medical device and advanced wound care markets, ... beds, patient lifting devices, and other healthcare equipment. ...
(Date:7/7/2015)... , July 7, 2015  Shareholder rights law ... a federal securities fraud class action complaint was ... Southern District of California.  The complaint alleges that ... CLDN ) violated the Securities Exchange Act of ... 2015, by making materially false and misleading statements ...
(Date:7/7/2015)... 7, 2015 According to ... Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, ... Alpha Emitters, Brachytherapy - Y-90), by Application (Oncology, ... by MarketsandMarkets, this report studies the global Nuclear ... to 2020. This market is expected to reach ...
Breaking Medicine Technology:Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 2Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 2Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 4
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: